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Cardiovascular risk factors 
A B S T R A C T   
Background: Prevalence of obesity, hypertension and dyslipidemia has been increasing in children and adoles-
cents worldwide. Exposure to environmental pollutants may contribute to this development. Our aim was to 
study associations between perfluoroalkyl substances (PFAS) and dyslipidemia, hypertension and obesity in a 
population-based sample of adolescents. 
Methods: Serum PFAS concentrations were measured in 940 adolescents, mean age 16.4 (SD 1.3) years, from the 
cross-sectional Fit Futures study by the UHPLC-MS/MS method. The following endpoints were used: hyperten-
sion (systolic blood pressure over 130 mmHg and/or diastolic blood pressure over 80 mmHg); obesity (body mass 
index over 2 z-score, WHO charts for adolescents); dyslipidemia (total cholesterol ≥ 5.17 mmol/L, and/or LDL- 
cholesterol ≥ 3.36 mmol/l, and/or apolipoprotein B ≥ 1.10 g/L). 
Results: Perfluorooctane sulfonate (PFOS), perfluorononanoate (PFNA), perfluorodecanoate (PFDA) and per-
fluoroundecanoate (PFUnDA) serum concentrations were positively associated with apolipoprotein B, total- and 
LDL cholesterol. The highest vs. lowest quartiles of total PFAS (
∑
PFAS), PFNA and PFDA concentrations were 
positively associated with the risk of dyslipidemia: OR 2.24 (95% CI 1.10–4.54), OR 2.30 (95% CI 1.16–4.57) and 
2.36 (95% CI 1.08–5.16), respectively. The highest vs. lowest quartiles of 
∑
PFAS, perfluorohexane sulfonate 
(PFHxS), PFOS, perfluorooctanoate (PFOA) concentrations were positively associated with the risk of hyper-
tension: OR 1.91 (95% CI 1.12–3.26), OR 2.06 (95% CI 1.16–3.65), 1.86 (95% CI 1.08–3.19) and 2.08 (95% CI 
1.17–3.69) respectively. PFHxS and perfluoroheptane sulfonate (PFHpS) concentrations were positively associ-
ated with obesity. 
Conclusions: This cross-sectional study showed a possible link between several PFAS and dyslipidemia, hyper-
tension and obesity in Norwegian adolescents.   
1. Introduction 
The process of atherosclerosis leading to cardiovascular disease 
starts in childhood and progresses further throughout the life-course. 
Cardiovascular risk factors in children and adolescents such as over-
weight and obesity, hypertension and dyslipidemia are associated with 
markers of atherosclerosis in aorta, carotid and coronary arteries 
(Berenson et al., 1998; Juhola et al., 2013; (Expert panel, 2011)). 
Prevalence of overweight and obesity in children and adolescents is 
increasing worldwide; the obesity epidemic is a major healthcare chal-
lenge and a matter of great concern (Skinner et al., 2016; Garnett et al., 
2016; Brettschneider et al., 2017). According to the last report from the 
World Health Organization, 18% of adolescents and children worldwide 
are overweight or obese, with the prevalence rising up to 33% in some 
countries (WHO). In Norway, overweight was found in 20% of girls and 
22% of boys of school age, and the prevalence of overweight and obesity 
has been increasing over the past three decades (Kolle et al., 2009; 
Juliusson et al., 2007; Krokstad, 2011; Evensen et al., 2016). Overweight 
and obesity are associated with hypertension and dyslipidemia in chil-
dren and adolescents (Sorof and Daniels, 2002). Hypertension is a major 
cardiovascular risk factor which contributes to development of stroke, 
myocardial infarction, heart failure, chronic kidney disease and pe-
ripheral artery disease later in life (Daniels, 2019). A recent 
meta-analysis of 47 studies from different populations showed a pooled 
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prevalence of hypertension of 4% in children and youth 19 years and 
younger (Song et al., 2019). There has been an increase in the preva-
lence of hypertension in children and adolescents probably due to the 
overweight epidemic, and the prevalence is consistently higher in boys 
compared to girls (Flynn et al., 2017). The prevalence of dyslipidemia 
has also been increasing in adolescent populations, and this disorder of 
lipid metabolism remains one of the major cardiovascular risk factors 
(Expert panel, 2011). One of the theories about the causes of the 
worldwide epidemic of overweight, obesity, hypertension and dyslipi-
demia is a combination of unfavorable diet choices, inadequate physical 
activity, psychosocial stress, as well as possible effects of environmental 
pollutant exposures, especially endocrine-disrupting chemicals (EDCs) 
(Schell et al., 2012). 
Several reports suggest that prenatal exposure to EDCs may increase 
risk of overweight and obesity in children (Valvi et al., 2012; Karlsen 
et al., 2017). There is emerging evidence that the newer group of POPs, 
perfluoroalkyl substances (PFAS), have endocrine disrupting properties 
and may be involved in the pathogenesis of dyslipidemia and weight 
gain (Pedersen et al., 2016; Geiger et al., 2014; Maisonet et al., 2015; 
Zeng et al., 2015). Exposure to several PFAS had a positive association 
with total cholesterol and LDL-cholesterol (Geiger et al., 2014; Maisonet 
et al., 2015; Zeng et al., 2015; ; Christensen et al., 2016; Koshy et al., 
2017; Seo et al., 2018; He et al., 2018; Mora et al., 2018; Li et al., 2020; 
Steenland et al., 2009). PFAS are environmentally persistent chemicals 
that are widely used in many consumer products since 1940s. PFAS are 
used in firefighting foams, paper-, textile-, and leather impregnation, 
cosmetics, in ski waxes and are by-products in polytetrafluoroethylene 
(PTFE) products as for example Teflon. Perfluorooctane sulfonate 
(PFOS) and perfluorooctanoate (PFOA) were relatively newly defined in 
the Stockholm convention as POPs (Stockholm Convention). Few studies 
have examined the possible unfavorable effects of PFAS on cardiovas-
cular risk factors in adolescents (Geiger et al., 2014; Maisonet et al., 
2015; Lin et al., 2009). The aim of our study was to investigate associ-
ations between serum concentrations of several PFAS and serum lipids 
concentrations, dyslipidemia, hypertension, overweight and obesity in a 
population-based cohort of adolescents in Northern Norway. 
2. Materials and methods 
2.1. The study population 
All first level high school students in the municipalities of Tromsø 
and Balsfjord in Northern Norway (n = 1117) were invited to participate 
in the Tromsø study Fit Futures 1 (TFF1) in 2010–2011, and 1038 
participated (93%), the majority aged 15–19 years (97%). The partici-
pants came to the Clinical Research Unit at the University Hospital of 
North Norway (UNN, Tromsø) for a half-day visit during school-hours. 
The participants filled in an electronic questionnaire including 143 
questions on family background, lifestyle (physical activity, use of 
chewed tobacco, smoking), dietary habits, and general health. The food 
frequency questionnaire (FFQ) used in the previous Tromsø study of 
adults was adapted for adolescents and its validity regarding informa-
tion on dietary habits for adolescents was previously assessed (Torris 
et al., 2017). The questionnaire had 29 dietary questions related to 
possible sources of environmental pollutants and information charac-
terizing healthy/unhealthy diet (e.g. intake of fruits and vegetables, fat 
fish and lean fish, dairy products, junk food and snacks). The example of 
the diet question: “How often do you usually eat vegetables?” (rar-
ely/never; 1–3 times per month; 1–3 times per week; 4–6 times per 
week; 1–2 times per day; 3–4 times per day; 5 times or more per day). 
Trained research nurses performed standardized height, weight and 
blood pressure measurements, blood sampling, and structured in-
terviews (medication and disease, in addition to menstruation and 
pregnancy in girls). Medication use was self-reported and later coded by 
a medical professional using the WHO Anatomical Therapeutic Chemi-
cal Classification System (ATC) codes. Altogether 940 participants 
provided blood samples for environmental pollutants analyses (84% of 
all first level high school students in the area who were invited to 
participate in the study). None of the girls were pregnant at the time of 
the TFF1 study. 
2.2. Ethics 
Written informed consent was obtained from all participants and 
those aged less than 16 years brought written informed consent from 
parents. The study was approved by the Regional Committee for Medical 
and Health Research Ethics, North Norway (2015/1384/REK nord). 
2.3. Physical examination 
Systolic and diastolic blood pressure (SBP, DBP) were measured 3 
times after 2-min seated rest on the participant’s right upper arm with an 
oscillometric digital automatic device Dinamap ProCare 300 monitor 
(GE Healthcare, Oslo, Norway), measurements being separated by a 1- 
min interval. The average of the second and the third SBP and DBP 
measurements was further used. Body height and weight were measured 
to the nearest 0.1 cm and 0.1 kg on a Jenix DS 102 Stadiometer (Dong 
Sahn Jenix, Seoul, Korea). Body mass index (BMI) was calculated as 
weight (kg)/height (m2). 
2.4. Laboratory analyses 
Blood samples for PFAS analyses were obtained from the antecubital 
vein in BD vacutainer® tubes with no additive (Becton, Dickinson and 
Company, New Jersey, US), and serum was transferred to Supelco glass 
vials (Sigma-Aldrich Norway AS, Oslo, Norway) with Pasteur glass pi-
pettes. Samples were stored at − 40 ◦C prior to PFAS analysis. All the 
equipment was tested for possible PFAS contamination and no sub-
stantial background PFAS contamination was detected. All laboratory 
analyses were performed at the Department of Laboratory Medicine, 
UNN. Sample preparation, instrumental analysis, quantification, accu-
racy and precision of the method for PFAS assessment, as well as quality 
controls have been described in detail in earlier publication (Huber and 
Brox, 2015). Concisely, samples were extracted automatically on the 
liquid handler Tecan Freedom Evo 200 (Männedorf, Switzerland). The 
ultrahigh pressure liquid chromatography triple-quadrupole mass-s-
pectrometry (UHPLC-MS/MS, Waters Acquity UPLC system, Xevo TQ-S 
mass spectrometer, Waters, Milford, MA, USA) was applied for analysis 
of perfluorobutane sulfonate (PFBS), perfluoropentane sulfonate (PFPS), 
perfluorohexane sulfonate (PFHxS), perfluoroheptane sulfonate 
(PFHpS), perfluorooctane sulfonate (PFOS), perfluorononane sulfonate 
(PFNS), perfluorodecane sulfonate (PFDS), perfluorododecane sulfonate 
(PFDoDS), perfluorooctane sulfonamide (PFOSA), perfluorohexanoate 
(PFHxA), perfluoroheptanoate (PFHpA), perfluorooctanoate (PFOA), 
perfluorononanoate (PFNA), perfluorodecanoate (PFDA), per-
fluoroundecanoate (PFUnDA), perfluorododecanoate (PFDoDA), per-
fluorotridecanoate (PFTrDA) and perfluorotetradecanoate (PFTeDA) 
concentrations in serum. Quantification was conducted applying the 
Masslynx and Targetlynx software (TargetLynx Application manager, 
Version 4.1, Waters, Milford, MA, USA (Waters)) and achieved by the 
internal-standard method with isotope-labelled PFAS. For quality con-
trol, four blank samples, four standard reference material (SRM) 1958 
samples (NIST, Gaithersburg, MD, USA) and three bovine serum samples 
(Sigma Aldrich, Steinheim, Germany) were analyzed within each batch 
of 96 samples. Differences from the assigned mean reference concen-
trations were between 5 and 11%. Analytical coefficient of variation 
(CV) was below 10% for all PFAS except for PFUnDA with CV 12%. 
Limits of detection (LOD), detection rates and ranges of PFAS concen-
trations in this population have been previously published (Averina 
et al., 2018). 
Total cholesterol, high-density lipoprotein (HDL) cholesterol, low- 
density lipoprotein (LDL) cholesterol were measured in fresh serum 
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samples by enzymatic colorimetric methods by the Cobas 8000 instru-
ment (Roche Diagnostics, F. Hoffmann-La Roche Ltd, Basel, 
Switzerland). CV was <2% for all the lipids analyses. Apolipoproteins 
A1 and B (apo A1, apo B) were measured in fresh serum samples by 
Cobas 8000 instrument by immunoturbidimetric methods standardized 
according to the IFCC SP1-01 and IFCC SP3-07 reference standards, 
respectively. CV was <3.5% for apo A and apo B. The Department of 
Laboratory Medicine, UNN, participates successfully in the external 
quality control programmes for biochemistry tests for serum lipids 
(Labquality, Helsinki, Finland; NOKLUS, Bergen, Norway) and in the 
international quality control programme for environmental pollutants 
(the Arctic Monitoring and Assessment, AMAP) Ring Test for Persistent 
Organic Pollutants in Human Serum, organized by the Laboratoire de 
toxicologie, Institut National de Santé Publique du Quebec, Canada). All 
the quality controls during the time of the study were within the 
acceptable limits. 
2.5. Definitions of clinical outcomes 
There were no records of medicines with the ATC codes C01-C10, so 
there were no participants using antihypertensive treatment or treat-
ment for dyslipidemia. Therefore, the definitions of hypertension and 
dyslipidemia were based only on the cut-off levels for blood pressure and 
serum lipids from the international guidelines for adolescents. 
Hypertension in adolescents was defined according to the American 
Academy of Pediatrics (AAP) 2017 guidelines for screening and man-
aging high blood pressure in children and adolescents (Flynn et al., 
2017): Hypertension: SBP ≥130 mmHg and/or DBP ≥80 mmHg. 
Dyslipidemia was defined according to the Integrated guidelines for 
cardiovascular health and risk reduction in children and adolescents, the 
National Heart, Lung and Blood Institute (Expert panel, 2011). One or 
several parameters define dyslipidemia: 
High total cholesterol ≥5.17 mmol/L (≥200 mg/dL). 
High LDL cholesterol ≥3.36 mmol/L (≥130 mg/dL). 
High apo B ≥ 1.10 g/L (≥110 mg/dL). 
Low HDL cholesterol <1.03 mmol/L (<40 mg/dL). 
Low apo A1 < 1.15 g/L (<115 mg/dL). 
Overweight was defined as BMI over 1 z-score (1 SD) and obesity as 
BMI over 2 z-score in the WHO BMI charts for children 5–19 years old 
(WHO). 
2.6. Statistical analyses 
Statistical analyses were performed by the SPSS program (IBM Corp. 
IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.). 
Chi-Square test and Student’s t-test were used to evaluate sex differences 
in lifestyle and cardiovascular risk factors. PFAS concentrations were 
not normally distributed, sex differences in PFAS concentrations were 
therefore evaluated by the non-parametric Mann-Whitney U test. 
Association between serum lipids concentrations, blood pressure, 
BMI and PFAS serum concentrations were assessed by multiple linear 
regression analyses. All the PFAS concentrations were log10-transformed 
before linear regression analyses because of the skewed distribution. The 
Targetlynx-software was used to calculate Limits of detection (LODs) for 
each individual sample (LODi) and each individual PFAS analyte with a 
signal to noise ratio of 3 divided by the related sample amount. Limit of 
quantification (LOQ) was defined as three times the LOD. To reduce 
possible bias of left censored data analyses the actual values between 
LOQ and LOD were used in the regression models. Individual PFAS 
concentrations below the LOD were replaced by LODi divided by 2. 
Multiple linear regression analyses of associations between PFAS and 
serum lipids were performed only for PFAS with detection rate ≥70%: 
PFHxS, PFHpS, PFHpA, PFOS, PFOA, PFNA, PFDA, PFUnDA. PFAS with 
detection rate <70% were included in the total PFAS concentration 
(ΣPFAS) defined as the sum of serum concentrations in ng/mL of all 18 
measured PFAS. Additionally, the Spearman correlation and the 
principle component analysis (PCA) was performed for PFAS serum 
concentrations. 
The selection of the possible confounders for the regression models 
was based on the previously published results from the Fit Futures study 
that showed significant associations of diet and some lifestyle variables 
with PFAS in this population (Averina et al., 2018). Alcohol intake was 
not substantial in this adolescent population and was not associated with 
PFAS, therefore it was not considered as a possible confounder. Directed 
acyclic graphs (DAGs) were used to present a sufficient set of covariates 
in the primary regression models (Suppl. Figs. 1-2). The following var-
iables were included in the primary regression models for serum lipids: 
age, sex, BMI, physical activity, use of chewed tobacco (snuff), and di-
etary variables such as intake of cheese, full fat and semi-skimmed dairy 
products, fat and lean fish, fish liver, junk food (sausages, pizza, 
hamburger), fruits and vegetables, snacks (chips, biscuits cakes and 
buns, candy and chocolate). Each dietary variable was included sepa-
rately in the regression models. Smoking was not associated with serum 
lipids, therefore it was not included in the regression models. For the 
regression analyses with serum triglycerides as dependent variables the 
covariate “time since last meal” was included in the models. Further, we 
used backward elimination procedure, which involves starting with all 
chosen covariates and stepwise deleting the variables whose loss is not 
important for the model fit. The results presented in the article are the 
final regression models after the Wald backward elimination and 
assessment of the goodness-of-fit of the regression models by the Akaike 
Information criterion (AIC). 
Associations between PFAS and categorical variables such as over-
weight, obesity, dyslipidemia and hypertension (yes vs. no) were 
assessed by the binary logistic regression analyses where PFAS con-
centrations were used as quartile categories. The following covariates 
were included in the primary logistic regression models for hyperten-
sion: age, sex, BMI, physical activity, smoking. The logistic regression 
models with obesity as dependent variable included age, sex, physical 
activity, smoking and diet. Smoking was removed from the final 
regression models for hypertension and obesity, diet was removed from 
the final regression models for obesity after goodness of fit estimation. 
Further, we present the results of the final regression models. No 
mathematical correction was made for multiple comparisons as only 
planned comparisons were performed. Statistical significance was 
concluded at a 2-tailed p-value <0.05. 
3. Results 
General characteristics of the study population are presented in 
Table 1. Altogether 445 girls and 495 boys, mean age 16.5 (SD 1.4) and 
16.3 (SD 1.1) years, respectively, were included in the study. Boys had 
higher prevalence of low HDL cholesterol than girls, while girls had 
higher prevalence of high total cholesterol and high LDL cholesterol. 
About 1/5 of the entire study population was overweight (21.4%), there 
was no gender difference in prevalence of overweight and obesity. Boys 
had higher mean systolic blood pressure and remarkably higher preva-
lence of hypertension than girls. Smoking was not different between the 
genders, however boys used more snuff than girls. Prevalence of 
sedentary lifestyle was also higher in boys. 
Table 2 presents serum PFAS and serum lipids concentrations. Girls 
had higher total cholesterol, higher HDL and LDL cholesterol, higher apo 
A1 and apo B than boys. Total sum PFAS (
∑
PFAS) concentrations were 
not different between boys and girls, however girls had higher PFOA, 
PFNA, PFDA and PFUnDA concentrations, while boys had higher PFHxS 
and PFOS concentrations. The entire study population had measurable 
concentrations of PFHxS (100% detection rate), PFOS (100% detection 
rate), PFOA (99.9% detection rate), PFNA (100% detection rate) and 
PFDA (99.7% detection rate). Detection rates for PFHpA and PFHpS 
were 74.8% and 97.7%, respectively. For other PFAS the detection rates 
were below 70%, and their concentrations were included in 
∑
PFAS 
(Suppl. Table 1). 
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3.1. PFAS and serum lipids 
Associations of serum lipids with serum PFAS concentrations are 
presented in Table 3. The results are from the final multiple linear 
regression models adjusted for age, sex, BMI, lifestyle and diet variables. 
The final regression models for total and LDL cholesterol with all 
covariates are presented in Suppl. Tables 4 and 5. Serum total choles-
terol, LDL cholesterol and apo B concentrations were positively associ-
ated with PFOS, PFNA, PFDA and PFUnDA. Serum HDL cholesterol and 
apo A1 were positively associated only with PFUnDA concentrations. 
ΣPFAS concentrations were significantly positively associated (p < 0.05) 
with apo B and LDL-cholesterol with β-coefficients 0.06 (95% CI 
0.002–0.13) and 0.27 (95% CI 0.02–0.52), respectively (data not shown 
in Table 3). There was no association between serum lipids and PFHxS, 
PFHpS, PFHpA and PFOA (data not shown). 
3.2. PFAS and dyslipidemia 
Logistic regression analyses with adjustment for age, sex, BMI and 
diet variables showed significant positive associations of dyslipidemia 
with 
∑
PFAS, PFOS, PFNA, PFDA and PFUnDA (Table 4). The associa-
tions of PFOS and PFUnDA with dyslipidemia were significant only for 
3rd quartile vs. 1st quartile, but not for the concentrations over the 4th 
quartile. Female gender and BMI, were positively associated with dys-
lipidemia. Low HDL and low apo A1 were not associated with individual 
PFAS concentrations; therefore, these parameters were not included in 
the dyslipidemia definition used in Table 4. 
3.3. PFAS and hypertension 
There was no significant association between blood pressure as a 
continuous variable and different serum PFAS concentrations tested in 
the linear regression analysis with adjustment for possible confounders. 
Age, male gender and BMI were positively associated with blood pres-
sure. The combined variable hypertension (SBP >130 and/or DBP>80 
mm Hg) in this adolescent population was positively associated with 
ΣPFAS, PFHxS, PFOA and PFOS concentrations over 4th quartile vs. 1st 
quartile after adjustment for possible confounders (Table 5). There was 
no association between hypertension and PFHpA, PFNA, PFDA, PFUnDA 
(data not shown). PFHpS concentrations over 4th quartile had a ten-
dency to a positive association with hypertension with OR 1.74 (95% CI 
0.97–3.11), p = 0.063 (compared with the 1st quartile). 
∑
PFAS had a positive association with hypertension and dyslipide-
mia, however we did not observe a stronger compound effect of 18 PFAS 
compared with the effects of single PFAS (Tables 4 and 5). Several PFAS 
serum concentrations included in 
∑
PFAS were weakly positively 
correlated with each other (Suppl. Table 2). PFOS was moderately 
correlated with PFOA and PFHxS with Spearman correlation coefficients 
(ρ) 0.40 and 0.44, respectively. Only PFHpS and PFOS, PFNA and PFDA 
were strongly positively correlated (ρ > 0.7). The PCA analysis of PFAS 
serum concentrations was performed. After the Scree plot evaluation 
and elimination of all components with eigenvalues <1.0, three prin-
ciple components (PC) were retained (Suppl. Table 3). PC1 was defined 
by PFHpA, PFOA, PFNA, PFDA; PC2 was defined by PFHxS, PFHpS, 
PFOS; PC3 was defined by PFHxA, PFUnDA, PFDoDA, PFTrDA. There 
was no strong correlation between the principle components (Suppl. 
Table 3). PC scores were generated from the PCA and included as 
covariates in the regression analyses instead of the 
∑
PFAS variable. PC2 
and PC3 scores were not statistically significantly associated with serum 
lipids and blood pressure when included in the regression models 
together with PC1. PC1 score had a significant positive association with 
systolic blood pressure, LDL-cholesterol and apolipoprotein B in the 
multiple linear regression analysis. PC1 score was significantly posi-
tively associated with hypertension in the logistic regression analysis 
(Suppl. Table 3). The results of the PCA compared with the regression 
analysis for single PFAS indicate that the positive association of PC1 
with hypertension was mostly due to PFOA effect, as other single PFAS 
that defined PC1 were not significantly associated with hypertension. 
The positive association of PC1 with dyslipidemia (high LDL-cholesterol 
and apo B) was mostly due to PFNA and PFDA effects. PFNA and PFDA 
were strongly positively correlated, their effects on dyslipidemia are 
difficult to separate from each other. 
Table 1 
Characteristics of the study population. The Tromsø study Fit Futures 1.  







Age (years), mean (SD) 16.5 (1.4) 16.3 (1.1) 0.014 
BMI (kg/m2), mean (SD) 22.6 (4.3) 22.4 (4.1) 0.615 
Overweight (BMI >1 z-score) 19.3% 23.2% 0.152 
Obesity (BMI >2 z-score) 5.4% 8.0% 0.120 
High total cholesterol ≥ 5.17 
mmol/L 
12.3% 5.1% <0.0001 
High LDL cholesterol ≥ 3.36 
mmol/L 
9.8% 5.7% 0.025 
High Apo B ≥ 1.10 g/L 0.9% 1.1% 0.998 
Low HDL <1.03 mmol/L 12.1% 25.3% <0.0001 
Low Apo A1 < 1.15 g/L 12.8% 32.0% <0.0001 
Systolic blood pressure, mean 
(SD)b 
111.6 (9.6) 122.7 (12.5) <0.0001 
Diastolic blood pressure, mean 
(SD)b 
62.8 (7.1) 63.7 (7.7) 0.050 
Hypertensionc 4.0% 28.9% <0.0001 
Dyslipidemiad 13.2% 6.5% 0.001 
Smoking 20.9% 23.0% 0.478 
Chewed tobacco use (snuff) 30.6% 39.6% 0.004 
Physical activity hard training/ 
sporte 
16.7% 22.7% 0.021 
Physical activity highe 28.3% 23.4% 0.098 
Physical activity moderatee 41.3% 24.9% <0.0001 
Sedentary lifestyle 13.7% 29.0% <0.0001  
a Pearson Chi Square test or t-test. 
b mmHg. 
c SBP≥130/80 mmHg. 
d total cholesterol ≥5.17 mmol/L (≥200 mg/dL) and/or LDL cholesterol ≥
3.36 mmol/L (≥130 mg/dL) and/or apo B ≥ 1.10 g/L (≥110 mg/dL). 
e Physical activity: hard training = regular hard training or sports competi-
tions several times per week, high = recreational sports and heavy outdoor ac-
tivities, moderate = walking, cycling or other moderate exercise at least 4 h per 
week. 
Table 2 
Serum lipids and perfluoroalkyl substances (PFAS) concentrations. The Tromsø 
study Fit Futures 1.  
Serum concentrations LODa Girls (n = 445)b Boys (n = 495)b p-valuec 
two-tailed 
∑
PFAS – 10.6 (4.77) 11.0 (4.76) 0.236 
PFHxS 0.02 ng/mL 0.80 (0.53) 0.95 (0.64) <0.0001 
PFHpS 0.01 ng/mL 0.14 (0.06) 0.16 (0.07) <0.0001 
PFOS 0.04 ng/mL 5.71 (2.64) 6.52 (3.09) <0.0001 
PFOA 0.30 ng/mL 2.14 (1.26) 1.86 (0.67) <0.0001 
PFNA 0.03 ng/mL 0.61 (0.40) 0.48 (0.20) <0.0001 
PFDA 0.03 ng/mL 0.27 (0.20) 0.19 (0.09) <0.0001 
PFUnDA 0.03 ng/mL 0.17 (0.13) 0.14 (0.10) <0.0001 
Total cholesterol 1.3 mmol/L 4.25 (0.72) 3.91 (0.77) <0.0001 
HDL cholesterol 0.1 mmol/L 1.45 (0.33) 1.24 (0.28) <0.0001 
LDL cholesterol 0.2 mmol/l 2.46 (0.65) 2.30 (0.70) <0.0001 
Triglycerides 0.1 mmol/L 1.05 (0.48) 1.13 (0.55) 0.023 
Apolipoprotein A1 0.25 g/L 1.37 (0.21) 1.22 (0.18) <0.0001 
Apolipoprotein B 0.20 g/L 0.66 (0.16) 0.61 (0.17) <0.0001  
a Level of detection (LOD). 
b For PFAS serum concentrations: geometric mean (interquartile range, IQR), 
ng/mL), geometric mean is 10β where β is a mean log 10 concentration; for 
serum lipids concentrations: mean (SD), for total cholesterol, HDL and LDL 
cholesterol in mmol/l, for apolipoproteins AI and B in g/L. 
c The Mann-Whitney U test for PFAS, t-test for lipids. 
M. Averina et al.                                                                                                                                                                                                                                
Environmental Research 195 (2021) 110740
5
3.4. PFAS and overweight/obesity 
Logistic regression analyses with adjustment for age, sex and phys-
ical activity outside school showed no association of overweight and 
obesity with total ΣPFAS, PFOS, PFOA, PFNA, PFDA and PFUnDA con-
centrations. After adjustment for sex, age and physical activity outside 
school, PFHxS and PFHpS concentrations were positively associated 
with obesity (Table 6). There was no significant association between 
BMI as a continuous variable and different serum PFAS concentrations in 
the linear regression analysis. 
4. Discussion 
PFAS are abundant in the environment, dietary intake is the main 
source of PFAS and the entire general population is exposed to these 
substances (Domingo and Nadal, 2017). PFOS and PFOA are defined as 
POPs in the Stockholm convention (Stockholm Convention) and their 
use is therefore restricted and controlled, while other PFAS are still not 
regulated. 
In the present population-based cross-sectional study of Norwegian 
adolescents, several PFAS (
∑
PFAS, PFHxS, PFOA, PFOS, PFNA, PFDA, 
PFUnDA) were positively associated with cardiovascular risk factors 
such as unfavorable lipid profile and hypertension. These associations 
remained positive after adjustment for possible confounders. The EFSA 
2020 report has concluded that there was clear evidence for an associ-
ation between exposure to PFOS, PFOA and PFNA and increase of serum 
total cholesterol (Schrenk et al., 2020). Meanwhile, the evidence for 
other PFAS was not sufficient to conclude about the positive association 
with total and LDL cholesterol according to the EFSA 2020 report 
(Schrenk et al., 2020) The results of the present study in adolescents 
showed a positive association of exposure to PFOS, PFNA, PFDA and 
PFUnDA with total cholesterol and LDL-cholesterol. These results are 
consistent with several previously published studies in adults (Geiger 
et al., 2014; Maisonet et al., 2015; Zeng et al., 2015; Bao et al., 2017; 
Christensen et al., 2016; Koshy et al., 2017; Seo et al., 2018; He et al., 
2018; Mora et al., 2018; Li et al., 2020; Steenland et al., 2009). There 
Table 3 
Associations of serum lipids with serum log 10-tranformed-PFAS serum concentrations after adjustment for possible confounders (multiple linear regression analyses). 
The Tromsø study Fit Futures 1.  
Parameters PFOS PFNA PFDA PFUnDA 
β-coef.a p-value β-coef.a p-value β-coef.a p-value β-coef.a p-value 
Total cholesterol 0.38 (0.10; 0.66) 0.008 0.15 (0.04; 0.26) 0.008 0.35 (0.12; 0.57) 0.003 0.35 (0.17; 0.53) <0.0001 
LDL-cholesterol 0.30 (0.05; 0.55) 0.021 0.14 (0.05; 0.24) 0.004 0.34 (0.14; 0.54) 0.001 0.24 (0.07; 0.40) 0.004 
HDL-cholesterol 0.08 (− 0.03; 0.20) 0.152 − 0.001(− 0.05; 0.04) 0.980 − 0.01 (− 0.10; 0.09) 0.923 0.14 (0.06; 0.21) <0.0001 
Triglycerides 0.006 (− 0.18; 0.20) 0.947 − 0.01 (− 0.08; 0.07) 0.902 0.01 (− 0.15; 0.17) 0.901 − 0.05 (− 0.18; 0.08) 0.435 
Apolipoprotein A1 0.03 (− 0.05; 0.11) 0.502 0.02 (− 0.03; 0.08) 0.440 0.03 (− 0.03; 0.09) 0.283 0.10 (0.05; 0.15) <0.0001 
Apolipoprotein B 0.07 (0.004; 0.13) 0.036 0.04 (0.02; 0.07) 0.001 0.09 (0.04; 0.14) <0.0001 0.05 (0.01; 0.09) 0.009  
a Final regression models adjusted for age, sex, BMI and for lifestyle and diet variables: total cholesterol for intake of junk food (sausages, pizza, hamburger), snacks 
(chips, biscuits cakes and buns), full fat dairy products, fat and lean fish; LDL-cholesterol and apolipoprotein B for intake of junk food, full fat dairy products, fat and 
lean fish; HDL-cholesterol for chewed tobacco use (snuff), vegetables intake, fish liver intake; apolipoprotein A1 for vegetables and fruits intake, fish liver, snacks and 
candy intake; triglycerides for physical activity, intake of cheese, fish liver and for time since the last meal. 
Table 4 
Association between PFAS serum concentrations and dyslipidemia in Norwegian adolescents. The Tromsø study 
Fit Futures 1.  










Quartile 1a 2.59–8.60 15/214 1.0  
Quartile 2 8.61–10.72 22/206 1.86 (0.90–3.86) 0.096 
Quartile 3 10.73–13.37 25/201 2.18 (1.06–4.47) 0.034 
Quartile 4 13.38–200.8 27/203 2.24 (1.10–4.54) 0.026 
PFOS 
Quartile 1a 1.28–4.86 17/214 1.0  
Quartile 2 4.87–6.21 22/207 1.66 (0.82–3.37) 0.161 
Quartile 3 6.22–7.80 31/192 2.43 (1.23–4.77) 0.010 
Quartile 4 7.81–99.2 19/211 1.36 (0.65–2.83) 0.411 
PFNA 
Quartile 1a 0.120–0.400 16/213 1.0  
Quartile 2 0.401–0.496 22/204 1.74 (0.85–3.55) 0.130 
Quartile 3 0.497–0.676 19/209 1.24 (0.59–2.63) 0.571 
Quartile 4 0.677–5.35 32/198 2.30 (1.16–4.57) 0.018 
PFDA 
Quartile 1a 0.016–0.157 11/213 1.0  
Quartile 2 0.158–0.207 26/201 2.34 (1.08–5.05) 0.031 
Quartile 3 0.208–0.288 25/206 2.19 (1.01–4.74) 0.048 
Quartile 4 0.289–1.89 27/204 2.36 (1.08–5.16) 0.031 
PFUnDA 
Quartile 1a 0.005–0.104 16/213 1.0  
Quartile 2 0.105–0.151 19/209 1.44 (0.68–3.06) 0.347 
Quartile 3 0.152–0.217 30/200 2.30 (1.14–4.63) 0.020 
Quartile 4 0.218–0.852 24/202 2.00 (0.95–4.20) 0.066  
a Reference group. 
b Number. 
c Adjusted for sex, age and diet (junk food, snacks, full fat dairy and fat fish intake). 
d Total cholesterol ≥5.17 mmol/L and/or LDL cholesterol ≥3.36 mmol/L and/or high apo B ≥ 1.10 g/L. 
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was no association of PFAS with higher HDL that has protective effect, 
only PFUnDA was positively associated with higher HDL cholesterol, as 
well as with higher total- and LDL-cholesterol. The similar association 
between PFUnDA and HDL-cholesterol was described in another study 
(Fu et al., 2014). 
The EFSA 2020 report on effects of PFAS has concluded that there is 
still insufficient evidence to suggest that PFAS are associated with hy-
pertension and more studies are needed (Schrenk et al., 2020). The re-
sults of this study showed a positive association of exposure to PFHxS, 
PFOS and PFOA with hypertension that is consistent with other studies 
(Bao et al., 2017; Huang et al., 2019). 
Unfavorable effects of PFAS on blood pressure and serum lipids seem 
plausible as they were also reported in experimental animal studies and 
cell cultures. Thus, a study of pregnant rats exposed to PFOS and PFNA 
found increased blood pressure in their offspring (Rogers et al., 2014). 
Previous studies in cell cultures demonstrated dose-dependent PFAS 
effects with increased lipid levels and increased expression of peroxi-
some proliferator-activated receptors (PPARɣ and PPARɑ), which seems 
to be the plausible biological mechanism that could explain the effect of 
PFAS on the lipid metabolism (Ma et al., 2018; Yamamoto et al., 2015; Li 
et al., 2018). 
Results from published literature examining associations between 
PFAS exposure and overweight/obesity are not consistent. Koshy T et al. 
found no association with overweight in American adolescents exposed 
to PFHxS, PFOA, PFOS, PFNA, PFDA (Koshy et al., 2017), while a 
Swedish prospective birth cohort study showed a positive association of 
PFOS and PFOA exposure with overweight/obesity (Lauritzen et al., 
2018). A large multicenter prospective cohort study (the European 
Youth Heart Study) showed that childhood exposure to PFOS and PFOA 
predicted adiposity at 15 and 21 years of age (Domazet et al., 2016). 
Several studies of prenatal PFAS exposure in humans demonstrated 
positive association with higher body weight later in life (Karlsen et al., 
2017; Lauritzen et al., 2018; Hartman et al., 2017; Mora et al., 2017; 
EFSA, 2018). The EFSA 2020 report has concluded that there is insuf-
ficient evidence for association between exposure to PFAS and obesity 
(Schrenk et al., 2020). The present study found a positive association 
between obesity and PFHxS and PFHpS concentrations, however this 
association was not linear and there was no positive association with 
other PFAS. Obesity is a complex disease with multifactorial etiology; 
differences between the populations may be attributable to different 
genetic and environmental factors, as well as differences in PFAS 
exposure and different time of follow-up. 
The present cross-sectional study observed that several individual 
PFAS were associated with cardiovascular risk factors already in 
adolescence. This is consistent with a recently published study from a 
national cohort of the US population demonstrating that 
∑
PFAS, PFOS; 
PFNA, PFDA and PFUnDA were associated with cardiovascular disease 
risk in the general population (Huang et al., 2018). 
∑
PFAS, PFOS, PFOA 
exposure have also been associated with several metabolomics bio-
markers associated with oxidative stress and cardiovascular dysfunction 
(Wang et al., 2017). 
The cross-sectional design is the main limitation of the present study. 
Therefore, the causality of PFAS associations with obesity, hypertension 
and dyslipidemia cannot be established. However, PFAS have relatively 
long half-life, therefore the cross-sectional nature of this study may be of 
lesser importance. Another limitation of the study is the definition of 
obesity by high BMI, which is a usual approach for epidemiological 
studies, but it has its limitations because BMI cannot differentiate be-
tween bone density, muscle mass, and body fat. The strengths of the 
study are that the PFAS exposure was measured by analyzing serum 
samples at the specialized laboratory for analysis of environmental 
Table 6 
Association between obesity and PFHpS, PFHxS serum concentrations in Nor-










Quartile 1a 0.18–0.55 9/226 1.0  
Quartile 2 0.56–0.71 20/217 2.09 (0.89–4.91) 0.090 
Quartile 3 0.72–1.12 24/209 2.71 (1.17–6.25) 0.020 
Quartile 4 1.13–84.72 11/224 1.18 (0.46–3.04) 0.729 
PFHpS 
Quartile 1a 0.01–0.12 7/226 1.0  
Quartile 2 0,13–0.15 19/211 2.73 (1.05–7.05) 0.039 
Quartile 3 0.16–0.19 20/218 2.84 (1.10–7.37) 0.032 
Quartile 4 0.20–7.62 18/221 2.36 (0.89–6.25) 0.084  
a Reference group. 
b Number. 
c Adjusted for sex, age, physical activity outside school. 
Table 5 
Association between PFAS serum concentrations and hypertension in Norwegian adolescents. The Tromsø study 
Fit Futures 1.  
PFAS Concentration ng/mL Hypertension/non-hypertensionb OR (95% CI)c for hypertensiond p-value 
∑
PFAS 
Quartile 1a 2.59–8.60 35/200 1.0  
Quartile 2 8.61–10.72 36/199 1.13 (0.64–1.99) 0.679 
Quartile 3 10.73–13.37 37/198 1.28 (0.72–2.27) 0.394 
Quartile 4 13.38–200.8 53/182 1.91 (1.12–3.26) 0.018 
PFHxS 
Quartile 1a 0.18–0.55 25/210 1.0  
Quartile 2 0.56–0.71 46/191 1.63 (0.90–2.94) 0.103 
Quartile 3 0.72–1.12 37/196 1.25 (0.69–2.28) 0.461 
Quartile 4 1.13–84.72 53/182 2.06 (1.16–3.65) 0.013 
PFOA 
Quartile 1a 0.28–1.56 35/202 1.0  
Quartile 2 1.57–1.92 42/192 1.28 (0.74–2.22) 0.370 
Quartile 3 1.93–2.44 47/187 1.45 (0.85–2.49) 0.175 
Quartile 4 2.45–13.97 37/198 2.08 (1.17–3.69) 0.013 
PFOS 
Quartile 1a 1.28–4.86 33/202 1.0  
Quartile 2 4.87–6.21 35/200 1.40 (0.78–2.51) 0.261 
Quartile 3 6.22–7.80 36/199 1.01 (0.56–1.80) 0.980 
Quartile 4 7.81–99.2 57/178 1.86 (1.08–3.19) 0.025  
a Reference group. 
b Number. 
c Adjusted for sex, age, BMI and physical activity outside school. 
d Systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥80 mmHg. 
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pollutants and that the study population was recruited from the general 
population that provided a representative sample of the adolescent 
population from Northern Norway. Another strength of the study is the 
possibility to adjust for possible confounders due to the comprehensive 
data available on diet and lifestyle factors. Thus, it is likely that the 
observed associations are applicable to other youth populations. 
In conclusion, after adjustment for age, sex and lifestyle factors, 
several PFAS concentrations remained positively associated with the 
risk of dyslipidemia, hypertension and obesity in this cross-sectional 
study of the adolescent population from Northern Norway. These find-
ings indicate possible harmful effects of PFAS on cardiovascular system 
and lipid metabolism that start in adolescence and may lead to cardio-
vascular disease later in life. Further prospective studies are required to 
confirm this hypothesis. 
Credit author statement 
Maria Averina: conceptualization, methodology, formal analysis, 
writing and original draft preparation, visualization. Jan Brox: super-
vision, resources, funding acquisition, writing- reviewing and editing. 
Sandra Huber: methodology, investigation, data curation, validation, 
writing- reviewing and editing. Anne-Sofie Furberg: conceptualization, 
project administration, resources, funding acquisition, writing- review-
ing and editing. 
Declaration of competing interest 
The authors declare that they have no known competing financial 
interests or personal relationships that could have appeared to influence 
the work reported in this paper. 
Acknowledgements 
The authors would like to thank the participants in the Fit Futures 
study. We are grateful to Sten Kristian Odden for assistance with sample 
preparation and instrumental analysis; the Clinical Research Unit, Uni-
versity Hospital of North Norway for facilitating the data collection in 
the Fit Futures cohort, and the Department of Laboratory Medicine, 
University Hospital of North Norway for technical and financial support 
of the present study; and the Northern Norway Regional Health Au-
thority (Helse Nord RHF) for its financial subsidies. 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.envres.2021.110740. 
References 
Averina, M., Brox, J., Huber, S., Furberg, A.S., 2018. Perfluoroalkyl substances in 
adolescents in northern Norway: lifestyle and dietary predictors. The Tromso study, 
Fit Futures 1. Environ. Int. 114, 123–130. 
Bao, W.W., Qian, Z.M., Geiger, S.D., Liu, E., Liu, Y., Wang, S.Q., et al., 2017. Gender- 
specific associations between serum isomers of perfluoroalkyl substances and blood 
pressure among Chinese: isomers of C8 Health Project in China. Sci. Total Environ. 
607–608, 1304–1312. 
Berenson, G.S., Srinivasan, S.R., Bao, W., Newman 3rd, W.P., Tracy, R.E., Wattigney, W. 
A., 1998. Association between multiple cardiovascular risk factors and 
atherosclerosis in children and young adults. The Bogalusa Heart Study. N. Engl. J. 
Med. 338 (23), 1650–1656. 
Brettschneider, A.K., Schienkiewitz, A., Schmidt, S., Ellert, U., Kurth, B.M., 2017. 
Updated prevalence rates of overweight and obesity in 4- to 10-year-old children in 
Germany. Results from the telephone-based KiGGS Wave 1 after correction for bias 
in parental reports. Eur. J. Pediatr. 176 (4), 547–551. 
Christensen, K.Y., Raymond, M., Thompson, B.A., Anderson, H.A., 2016. Perfluoroalkyl 
substances in older male anglers in Wisconsin. Environ. Int. 91, 312–318. 
Daniels, S.R., 2019. Understanding the global prevalence of hypertension in children and 
adolescents. JAMA Pediatr (Oct 7), 1–2. https://doi.org/10.1001/ 
jamapediatrics.2019.3333. 
Domazet, S.L., Grontved, A., Timmermann, A.G., Nielsen, F., Jensen, T.K., 2016. 
Longitudinal associations of exposure to perfluoroalkylated substances in childhood 
and adolescence and indicators of adiposity and glucose metabolism 6 and 12 Years 
later: the European youth heart study. Diabetes Care 39 (10), 1745–1751. 
Domingo, J.L., Nadal, M., 2017. Per- and polyfluoroalkyl substances (PFASs) in food and 
human dietary intake: a review of the recent scientific literature. J. Agric. Food 
Chem. 65 (3), 533–543. 
EFSA, 2018. Risk to human health related to the presence of perfluorooctane sulfonic 
acid and perfluorooctanoic acid in food. EFSA Journal 16 (12), 5194. 
Evensen, E., Wilsgaard, T., Furberg, A.S., Skeie, G., 2016. Tracking of overweight and 
obesity from early childhood to adolescence in a population-based cohort - the 
Tromso Study, Fit Futures. BMC Pediatr. 16, 64. 
Expert panel, 2011. Expert Panel on Integrated Guidelines for Cardiovascular Health and 
Risk Reduction in Children and Adolescents: Summary Report. Pediatrics 128 (5), 
S213–S256. 
Flynn, J.T., Kaelber, D.C., Baker-Smith, C.M., Blowey, D., Carroll, A.E., Daniels, S.R., 
et al., 2017. Clinical practice guideline for screening and management of high blood 
pressure in children and adolescents. Pediatrics 140 (3), e20171904. 
Fu, Y., Wang, T., Fu, Q., Wang, P., Lu, Y., 2014. Associations between serum 
concentrations of perfluoroalkyl acids and serum lipid levels in a Chinese 
population. Ecotoxicol. Environ. Saf. 106, 246–252. 
Garnett, S.P., Baur, L.A., Jones, A.M., Hardy, L.L., 2016. Trends in the prevalence of 
morbid and severe obesity in Australian children aged 7-15 Years, 1985-2012. PloS 
One 11 (5), e0154879. 
Geiger, S.D., Xiao, J., Ducatman, A., Frisbee, S., Innes, K., Shankar, A., 2014. The 
association between PFOA, PFOS and serum lipid levels in adolescents. Chemosphere 
98, 78–83. 
Hartman, T.J., Calafat, A.M., Holmes, A.K., Marcus, M., Northstone, K., Flanders, W.D., 
et al., 2017. Prenatal exposure to perfluoroalkyl substances and body fatness in girls. 
Child. Obes. 13 (3), 222–230. 
He, X., Liu, Y., Xu, B., Gu, L., Tang, W., 2018. PFOA is associated with diabetes and 
metabolic alteration in US men: national Health and Nutrition Examination Survey 
2003-2012. Sci. Total Environ. 625, 566–574. 
Huang, M., Jiao, J., Zhuang, P., Chen, X., Wang, J., Zhang, Y., 2018. Serum 
polyfluoroalkyl chemicals are associated with risk of cardiovascular diseases in 
national US population. Environ. Int. 119, 37–46. 
Huang, R., Chen, Q., Zhang, L., Luo, K., Chen, L., Zhao, S., et al., 2019. Prenatal exposure 
to perfluoroalkyl and polyfluoroalkyl substances and the risk of hypertensive 
disorders of pregnancy. Environ. Health 18 (1), 5. 
Huber, S., Brox, J., 2015. An automated high-throughput SPE micro-elution method for 
perfluoroalkyl substances in human serum. Anal. Bioanal. Chem. 407 (13), 
3751–3761. 
Juhola, J., Magnussen, C.G., Berenson, G.S., Venn, A., Burns, T.L., Sabin, M.A., et al., 
2013. Combined effects of child and adult elevated blood pressure on subclinical 
atherosclerosis: the International Childhood Cardiovascular Cohort Consortium. 
Circulation 128 (3), 217–224. 
Juliusson, P.B., Roelants, M., Eide, G.E., Hauspie, R., Waaler, P.E., Bjerknes, R., 2007. 
Overweight and obesity in Norwegian children: secular trends in weight-for-height 
and skinfolds. Acta Paediatr. 96 (9), 1333–1337. 
Karlsen, M., Grandjean, P., Weihe, P., Steuerwald, U., Oulhote, Y., Valvi, D., 2017. Early- 
life exposures to persistent organic pollutants in relation to overweight in preschool 
children. Reprod. Toxicol. 68, 145–153. 
Kolle, E., Steene-Johannessen, J., Holme, I., Andersen, L.B., Anderssen, S.A., 2009. 
Secular trends in adiposity in Norwegian 9-year-olds from 1999-2000 to 2005. BMC 
Publ. Health 9, 389. 
Koshy, T.T., Attina, T.M., Ghassabian, A., Gilbert, J., Burdine, L.K., Marmor, M., et al., 
2017. Serum perfluoroalkyl substances and cardiometabolic consequences in 
adolescents exposed to the World Trade Center disaster and a matched comparison 
group. Environ. Int. 109, 128–135. 
Krokstad, S.K.M., 2011. Folkehelse i endring: helseundersøkelsen Nord-Trøndelag : 
HUNT 1 (1984-86) - HUNT 2 (1995-97) - HUNT 3 (2006-08). Levanger, HUNT 
forskningssenter. 
Lauritzen, H.B., Larose, T.L., Oien, T., Sandanger, T.M., Odland, J.O., van de Bor, M., 
et al., 2018. Prenatal exposure to persistent organic pollutants and child overweight/ 
obesity at 5-year follow-up: a prospective cohort study. Environ. Health 17 (1), 9. 
Li, C.H., Ren, X.M., Ruan, T., Cao, L.Y., Xin, Y., Guo, L.H., et al., 2018. Chlorinated 
polyfluorinated ether sulfonates exhibit higher activity toward peroxisome 
proliferator-activated receptors signaling pathways than perfluorooctanesulfonate. 
Environ. Sci. Technol. 52 (5), 3232–3239. 
Li, Y., Barregard, L., Xu, Y., Scott, K., Pineda, D., Lindh, C.H., et al., 2020. Associations 
between perfluoroalkyl substances and serum lipids in a Swedish adult population 
with contaminated drinking water. Environ. Health 19 (1), 33. 
Lin, C.Y., Chen, P.C., Lin, Y.C., Lin, L.Y., 2009. Association among serum perfluoroalkyl 
chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults. 
Diabetes Care 32 (4), 702–707. 
Ma, Y., Yang, J., Wan, Y., Peng, Y., Ding, S., Li, Y., et al., 2018. Low-level 
perfluorooctanoic acid enhances 3 T3-L1 preadipocyte differentiation via altering 
peroxisome proliferator activated receptor gamma expression and its promoter DNA 
methylation. J. Appl. Toxicol. 38 (3), 398–407. 
Maisonet, M., Nayha, S., Lawlor, D.A., Marcus, M., 2015. Prenatal exposures to 
perfluoroalkyl acids and serum lipids at ages 7 and 15 in females. Environ. Int. 82, 
49–60. 
Mora, A.M., Oken, E., Rifas-Shiman, S.L., Webster, T.F., Gillman, M.W., Calafat, A.M., 
et al., 2017. Prenatal exposure to perfluoroalkyl substances and adiposity in early 
and mid-childhood. Environ. Health Perspect. 125 (3), 467–473. 
Mora, A.M., Fleisch, A.F., Rifas-Shiman, S.L., Woo Baidal, J.A., Pardo, L., Webster, T.F., 
et al., 2018. Early life exposure to per- and polyfluoroalkyl substances and mid- 
childhood lipid and alanine aminotransferase levels. Environ. Int. 111, 1–13. 
M. Averina et al.                                                                                                                                                                                                                                
Environmental Research 195 (2021) 110740
8
Pedersen, K.E., Letcher, R.J., Sonne, C., Dietz, R., Styrishave, B., 2016. Per- and 
polyfluoroalkyl substances (PFASs) - New endocrine disruptors in polar bears (Ursus 
maritimus)? Environ. Int. 96, 180–189. 
Rogers, J.M., Ellis-Hutchings, R.G., Grey, B.E., Zucker, R.M., Norwood Jr., J., Grace, C.E., 
et al., 2014. Elevated blood pressure in offspring of rats exposed to diverse chemicals 
during pregnancy. Toxicol. Sci. 137 (2), 436–446. 
Schell, L.M., Burnitz, K.K., Gallo, M.V., 2012. Growth as a mirror: is endocrine disruption 
challenging Tanner’s concept? Ann. Hum. Biol. 39 (5), 361–371. 
Schrenk, D.B.M., Bodin, L., Chipman, J.K., del Mazo, J., Grasl-Kraupp, B., et al., 2020. 
Risk to human health related to the presence of perfluoroalkyl substances in food. 
EFSA Journal 18 (9), 6223. 
Seo, S.H., Son, M.H., Choi, S.D., Lee, D.H., Chang, Y.S., 2018. Influence of exposure to 
perfluoroalkyl substances (PFASs) on the Korean general population: 10-year trend 
and health effects. Environ. Int. 113, 149–161. 
Skinner, A.C., Perrin, E.M., Skelton, J.A., 2016. Prevalence of obesity and severe obesity 
in US children, 1999-2014. Obesity 24 (5), 1116–1123. 
Song, P., Zhang, Y., Yu, J., Zha, M., Zhu, Y., Rahimi, K., et al., 2019. Global prevalence of 
hypertension in children: a systematic review and meta-analysis. JAMA Pediatr 173 
(12), 1–10. 
Sorof, J., Daniels, S., 2002. Obesity hypertension in children: a problem of epidemic 
proportions. Hypertension 40 (4), 441–447. 
Steenland, K., Tinker, S., Frisbee, S., Ducatman, A., Vaccarino, V., 2009. Association of 
perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among 
adults living near a chemical plant. Am. J. Epidemiol. 170 (10), 1268–1278. 
Torris, C., Molin, M., Smastuen, M.C., 2017. Lean fish consumption is associated with 
beneficial changes in the metabolic syndrome components: a 13-year follow-up 
study from the Norwegian tromso study. Nutrients 9 (3), 247. 
Valvi, D., Mendez, M.A., Martinez, D., Grimalt, J.O., Torrent, M., Sunyer, J., et al., 2012. 
Prenatal concentrations of polychlorinated biphenyls, DDE, and DDT and overweight 
in children: a prospective birth cohort study. Environ. Health Perspect. 120 (3), 
451–457. 
Wang, X., Liu, L., Zhang, W., Zhang, J., Du, X., Huang, Q., et al., 2017. Serum 
metabolome biomarkers associate low-level environmental perfluorinated 
compound exposure with oxidative/nitrosative stress in humans. Environ. Pollut. 
229, 168–176. 
Waters. TARGETLYNX application manager. Available from: https://www.waters. 
com/webassets/cms/library/docs/720001733en.pdf. 
WHO. Growth reference 5-19 years, BMI for age 5-19 years. World Health Organization; 
[Available from: https://www.who.int/growthref/who2007_bmi_for_age/en/. 
Yamamoto, J., Yamane, T., Oishi, Y., Kobayashi-Hattori, K., 2015. Perfluorooctanoic acid 
binds to peroxisome proliferator-activated receptor gamma and promotes adipocyte 
differentiation in 3T3-L1 adipocytes. Biosci. Biotechnol. Biochem. 79 (4), 636–639. 
Zeng, X.W., Qian, Z., Emo, B., Vaughn, M., Bao, J., Qin, X.D., et al., 2015. Association of 
polyfluoroalkyl chemical exposure with serum lipids in children. Sci. Total Environ. 
512–513, 364–370. 
WHO. Global Health Observatory (GHO) data. Overweight and obesity. (Accessed 19 
January 2021). 
Stockholm Convention: Protecting human health and the environment from persistent 
organic pollutants. (Accessed 19 January 2021). 
M. Averina et al.                                                                                                                                                                                                                                
